Shots:
- Engitix to receive up front with additional payments based on the confirmation and functional validation of selected targets and is eligible to receive $500M as preclinical, development, regulatory and commercial milestones along with royalties on sales of therapies
- Takeda to get the exclusive rights to develop and commercialize the candidate emerges from the collaboration. The companies will validate the targets and preclinical development of therapeutics in liver fibrosis
- The agreement will focus on developing novel therapies for advanced fibrotic liver diseases, including NASH. The collaboration integrates Engitix’s ECM platform with Takeda’s expertise in gastroenterology R&D and commercialization
Click here to read full press release/ article | Ref: PRNewswire | Image: Ali Miller RD
